Hormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifen

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 255-263

  Dowsett, M ^a   Haynes, B P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Estradiol; Hormonal effects; Premenopausal; Tamoxifen; YM511

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; DINORTAMOXIFEN; ESTRADIOL; ESTROGEN; ESTRONE; FORMESTANE; NORTAMOXIFEN; SEX HORMONE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG; VOROZOLE;

ANDROSTENEDIONE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; ESTRONE BLOOD LEVEL; HORMONE ACTION; HORMONE INHIBITION; HUMAN; PREMENOPAUSE; TESTOSTERONE BLOOD LEVEL; TUMOR GROWTH;

EID: 0242457704     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00365-0     Document Type: Conference Paper

References (64)

1. Brueggemeier R.W. Aromatase inhibitors in breast cancer therapy. Expert Rev. Anticancer Ther. 2:2002;181-191.
2. Buzdar A.U., Robertson J.F., Eiermann W., Nabholtz J.M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 95:2002;2006-2016.
3. Njar V.C., Brodie A.M. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs. 58:1999;233-255.
4. Johannessen D.C., Engan T., Di Salle E., Zurlo M.G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S., Lonning P.E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 3:1997;1101-1108.
5. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., Lonning P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer. 74:1996;1286-1291.
6. Geisler J., Haynes B., Anker G., Dowsett M., Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20:2002;751-757.
7. Geisler J., King N., Anker G., Ornati G., Di Salle E., Lonning P.E., Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4:1998;2089-2093.
8. Dowsett M., Jones A., Johnston S.R., Jacobs S., Trunet P., Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res. 1:1995;1511-1515.
9. Trunet P.F., Mueller P., Bhatnagar A.S., Dickes I., Monnet G., White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J. Clin. Endocrinol. Metab. 77:1993;319-323.
10. Iveson T.J., Smith I.E., Ahern J., Smithers D.A., Trunet P.F., Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 77:1993;324-331.
11. Plourde P.V., Dyroff M., Dowsett M., Demers L., Yates R., Webster A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J. Steroid. Biochem. Mol. Biol. 53:1995;175-179.
12. Bajetta E., Zilembo N., Dowsett M., Guillevin L., Di Leo A., Celio L., Martinetti A., Marchiano A., Pozzi P., Stani S., Bichisao E. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur. J. Cancer. 35:1999;208-213.
13. Drug data sheet for Synacthen Ampoules 250 μg, Alliance Pharmaceuticals, 2001.
14. Abdu T.A., Elhadd T.A., Neary R., Clayton R.N. Comparison of the low dose short synacthen test (1 μg), the conventional dose short synacthen test (250 μg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J. Clin. Endocrinol. Metab. 84:1999;838-843.
15. Gonzalbez J., Villabona C., Ramon J., Navarro M.A., Gimenez O., Ricart W., Soler J. Establishment of reference values for standard dose short synacthen test (250 μg), low dose short synacthen test (1 μg) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects. Clin. Endocrinol. (Oxford). 53:2000;199-204.
16. Hurel S.J., Thompson C.J., Watson M.J., Harris M.M., Baylis P.H., Kendall-Taylor P. The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis. Clin. Endocrinol. (Oxford). 44:1996;141-146.
17. Wang T.W., Wong M.S., Smith J.F., Howlett T.A. The use of the short tetracosactrin test for the investigation of suspected pituitary hypofunction. Ann Clin. Biochem. 33:1996;112-118.
18. J.M. Dixon, Personal communication, 2002.
19. Santen R.J., Samojlik E., Wells S.A. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab. 51:1980;473-477.
20. Harris A.L., Dowsett M., Jeffcoate S.L., McKinna J.A., Morgan M., Smith I.E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. 55:1982;718-722.
21. Wander H.E., Blossey H.C., Nagel G.A. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 22:1986;1371-1374.
22. Stein R.C., Dowsett M., Hedley A., Gazet J.C., Ford H.T., Coombes R.C. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer. 62:1990;679-683.
23. Shetty G., Krishnamurthy H., Krishnamurthy H.N., Bhatnagar S., Moudgal R.N. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J. Steroid. Biochem. Mol. Biol. 61:1997;157-166.
24. Mitwally M.F., Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril. 75:2001;305-309.
25. Mitwally M.F., Casper R.F. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders (1). Fertil. Steril. 77:2002;776-780.
26. Harper-Wynne C.L., Sacks N.P., Shenton K., MacNeill F.A., Sauven P., Laidlaw I.J., Rayter Z., Miall S., Howes A., Salter J., Hills M.J., Lowe F.M., A'Hern R., Nasiri N., Doody D., Iqbal J., Dowsett M. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J. Clin. Oncol. 20:2002;1026-1035.
27. M. Baum, A.V. Buzdar, J. Cuzick, J. Forbes, J.H. Houghton, J.G. Klijn, T. Sahmoud; ATAC Trialist's Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 (2002) 2131-2139.
28. Lien E.A., Anker G., Lonning P.E., Solheim E., Ueland P.M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50:1990;5851-5857.
29. Dowsett M., Tobias J.S., Howell A., Blackman G.M., Welch H., King N., Ponzone R., von Euler M., Baum M. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer. Br. J. Cancer. 79:1999;311-315.
30. M. Dowsett, J. Cuzick, A. Howell, I. Jackson; ATAC Trialist's Group, Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial, Br. J. Cancer 85 (2001) 317-324.
31. Dowsett M., Pfister C., Johnston S.R., Miles D.W., Houston S.J., Verbeek J.A., Gundacker H., Sioufi A., Smith I.E. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin. Cancer Res. 5:1999;2338-2343.
32. Chander S.K., McCague R., Luqmani Y., Newton C., Dowsett M., Jarman M., Coombes R.C. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 51:1991;5851-5858.
33. Ingle J.N., Suman V.J., Johnson P.A., Krook J.E., Mailliard J.A., Wheeler R.H., Loprinzi C.L., Perez E.A., Jordan V.C., Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res. 5:1999;1642-1649.
34. Peyrade F., Frenay M., Etienne M.C., Ruch F., Guillemare C., Francois E., Namer M., Ferrero J.M., Milano G. Age-related difference in tamoxifen disposition. Clin. Pharmacol. Ther. 59:1996;401-410.
35. Buzdar A.U., Hortobagyi G.N., Frye D., Ho D., Booser D.J., Valero V., Holmes F.A., Birmingham B.K., Bui K., Yeh C.et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J. Clin. Oncol. 12:1994;50-54.
36. de Vos D., Slee P.H., Stevenson D., Briggs R.J. Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 31:1992;76-78.
37. Langan-Fahey S.M., Tormey D.C., Jordan V.C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer. 26:1990;883-888.
38. Lien E.A., Solheim E., Lea O.A., Lundgren S., Kvinnsland S., Ueland P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49:1989;2175-2183.
39. Etienne M.C., Milano G., Fischel J.L., Frenay M., Francois E., Formento J.L., Gioanni J., Namer M. Tamoxifen metabolism: pharmacokinetic and in vitro study. Br. J. Cancer. 60:1989;30-35.
40. Stevenson D., Briggs R.J., Chapman D.J., De Vos D. Determination of tamoxifen and five metabolites in plasma. J. Pharmaceut. Biomed. Anal. 6:1988;1065-1068.
41. Slee P.H., De Vos D., Chapman D., Stevenson D. The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients. Pharm. Weekbl. Sci. 10:1988;22-25.
42. Milano G., Etienne M.C., Frenay M., Khater R., Formento J.L., Renee N., Moll J.L., Francoual M., Berto M., Namer M. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br. J. Cancer. 55:1987;509-512.
43. McVie J.G., Simonetti G.P., Stevenson D., Briggs R.J., Guelen P.J., de Vos D. The bioavailability of Tamoplex (tamoxifen). Part 1. A pilot study. Meth. Find Exp. Clin. Pharmacol. 8:1986;505-512.
44. Bratherton D.G., Brown C.H., Buchanan R., Hall V., Kingsley Pillers E.M., Wheeler T.K., Williams C.J. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br. J. Cancer. 50:1984;199-205.
45. Kemp J.V., Adam H.K., Wakeling A.E., Slater R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol. 32:1983;2045-2052.
46. Daniel P., Gaskell S.J., Bishop H., Campbell C., Nicholson R.I. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur. J. Cancer Clin. Oncol. 17:1981;1183-1189.
47. J.S. Patterson, R.S. Settatree, H.K. Adam, J.V. Kemp, Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response, Eur. J. Cancer Suppl. (1980) 89-92.
48. Lyman S.D., Jordan V.C. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. Biochem. Pharmacol. 34:1985;2795-2806.
49. Foster A.B., Jarman M., Leung O.T., McCague R., Leclercq G., Devleeschouwer N. Hydroxy derivatives of tamoxifen. J. Med. Chem. 28:1985;1491-1497.
50. Jordan V.C., Bain R.R., Brown R.R., Gosden B., Santos M.A. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 43:1983;1446-1450.
51. Jordan V.C., Lieberman M.E., Cormier E., Koch R., Bagley J.R., Ruenitz P.C. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol. Pharmacol. 26:1984;272-278.
52. Katzenellenbogen B.S., Miller M.A., Eckert R.L., Sudo K. Antiestrogen pharmacology and mechanism of action. J. Steroid. Biochem. 19:1983;59-68.
53. Robertson D.W., Katzenellenbogen J.A., Long D.J., Rorke E.A., Katzenellenbogen B.S. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid. Biochem. 16:1982;1-13.
54. Fabian C., Tilzer L., Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm. Drug Dispos. 2:1981;381-390.
55. Jordan V.C., Collins M.M., Rowsby L., Prestwich G.A. Monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75:1977;305-316.
56. Dowsett M., Donaldson K., Tsuboi M., Wong J., Yates R. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother. Pharmacol. 46:2000;35-39.
57. Alonso-Munoz M.C., Ojeda-Gonzalez M.B., Beltran-Fabregat M., Dorca-Ribugent J., Lopez-Lopez L., Borras-Balada J., Cardenal-Alemany F., Gomez-Batiste X., Fabregat-Mayol J., Viladiu-Quemada P. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology. 45:1988;350-353.
58. Ingle J.N., Green S.J., Ahmann D.L., Long H.J., Edmonson J.H., Rubin J., Chang M.N., Creagan E.T. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol. 4:1986;958-964.
59. Rose C., Kamby C., Mouridsen H.T., Andersson M., Bastholt L., Moller K.A., Andersen J., Munkholm P., Dombernowsky P., Christensen I.J. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res. Treat. 61:2000;103-110.
60. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
61. Vermeulen A., Deslypere J.P., Paridaens R., Leclercq G., Roy F., Heuson J.C. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22:1986;515-525.
62. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464.
63. Fishman J., Nisselbaum J.S., Menendez-Botet C.J., Schwartz M.K. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J. Steroid. Biochem. 8:1977;893-896.
64. Johnston S.R., Haynes B.P., Sacks N.P., McKinna J.A., Griggs L.J., Jarman M., Baum M., Smith I.E., Dowsett M. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res. Treat. 28:1993;241-250.